missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ c-Met Biosimilar Recombinant Monoclonal Antibody

Descripción
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term Korea RIBB patent anti-cMet.
MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.
Especificaciones
Especificaciones
| Antígeno | c-Met Biosimilar |
| Aplicaciones | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Clasificación | Recombinant Monoclonal |
| Concentración | 1 mg/mL |
| Conjugado | Unconjugated |
| Formulación | 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 |
| Especie del huésped | Human |
| Método de purificación | Protein A |
| Cantidad | 100 μg |
| Estado normativo | RUO |
| Mostrar más |
Título del producto
Al hacer clic en Enviar, acepta que Fisher Scientific se ponga en contacto con usted en relación con los comentarios que ha proporcionado en este formulario. No compartiremos su información para ningún otro fin. Toda la información de contacto proporcionada se mantendrá de acuerdo con nuestra Política de Privacidad. Política de privacidad.
¿Detecta una oportunidad de mejora?